Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy.

Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. Abstract Text:

Barak Zafrir,Shai Cohen,

BACKGROUND: Recent updated guidelines expand the usage of lipid-lowering therapy for primary prevention in high-risk individuals without an established cardiovascular disease (CVD). In contrast to secondary prevention, the extent of the target population and the utilization of lipid-lowering drugs are insufficiently clear. We examine the implementation of statin therapy as primary prevention in high-risk patients without a known CVD and discuss the rationale for the management of dyslipidemia in this population. METHODS: Records of 371 consecutive patients without an established CVD who were hospitalized in an internal medicine department between January and June 2005 were evaluated for CVD-equivalent high-risk factors (diabetes mellitus, stroke of carotid origin, peripheral vascular disease, abdominal aortic aneurysm, or Framingham 10-year risk score >/=20%). Demographic and clinical data, in addition to lipid profile and usage of statin drugs prior to and during hospitalization, were analyzed. RESULTS: Of the 371 non-cardiovascular patients, 88 (24%) were defined as high-risk individuals eligible for statin therapy as primary prevention of CVD. Their mean age was 71+/-11 years and their mean LDL-C level was 132+/-30 mg/dL. Seventeen patients (19%) were treated with statin drugs prior to admission and only two more patients (19/88, 22%) received statins in addition during hospitalization. Patients treated with statins had non-significantly higher LDL-C levels. CONCLUSIONS: There is considerable undertreatment of high-risk patients without an established CVD with lipid-lowering drugs. There is also sub-optimal implementation of guidelines in clinical practice, despite well-established evidence of the benefits of statins in the primary prevention of CVD for high-risk individuals with average cholesterol levels, diabetes mellitus, and in elderly patients, as represented by our study population.

Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. Publishing Authors By Initials

B Zafrir,S Cohen,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: European journal of internal medicine

VOLUME: 17

Page Numbers: 495-9

Journal Abbreviation: Eur. J. Intern. Med.

ISSN: 0953-6205

DAY: 13

MONTH: Nov

YEAR: 2006

Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9003220

Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy.

AFFILIATION: Department of Internal Medicine B, Lady Davis Carmel Medical Center, Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, 7 Michal St., Haifa 34362, Israel.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Intern Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy Related Publications

• A polymorphism in New Zealand inbred mouse strains that inactivates phosphatidylcholine transfer protein.
• A standards-based approach for facilitating discovery of learning objects at the point of care.
• Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts.
• Biomarkers in the diagnosis of Alzheimer's disease: are we ready?
• Cognitive predictors of functional decline in vascular dementia.
• Crohn's disease arthritis treated with infliximab: an open trial in four patients.
• Cryosurgery of the prostate: techniques and indications.
• Determination of ethylenediaminetetra-acetic acid in aqueous rinses of detergent-washed rubber stoppers of pharmaceutical vials using solid-phase extraction and capillary gas chromatography.
• Electrical activation of the human vestibulo-sympathetic reflex.
• Functional magnetic resonance imaging and magnetoencephalography differences associated with APOEepsilon4 in young healthy adults.
• Homozygous disruption of Pctp modulates atherosclerosis in apolipoprotein E-deficient mice.
• Identification and characterization of a human monoclonal antagonistic antibody AL-57 that preferentially binds the high-affinity form of lymphocyte function-associated antigen-1.
• Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog.
• Impulsivity and the reinforcing value of cigarette smoking.
• Management of refractory ulcerative colitis.
• Mental health services for victims of disasters.
• Mental health services in primary care in 'developing' countries.
• Optimism, distress, health-related quality of life, and change in cancer antigen 125 among patients with ovarian cancer undergoing chemotherapy.
• Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3.
• Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy.
• Social role and birth cohort influences on gender-linked personality traits in women: a 20-year longitudinal analysis.
• TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome.
• The cost-effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi.
• The physics of optimal decision making: a formal analysis of models of performance in two-alternative forced-choice tasks.
• The proximal convoluted tubule is a target for the uroguanylin-regulated natriuretic response.
• Treatment strategies for medulloblastoma and primitive neuroectodermal tumors.
• Writing about the benefits of an interpersonal transgression facilitates forgiveness.
• [Spatial orientation of the vestibulo-ocular reflex]
• [The effects of neuroleptics and social research in psychopharmacology.]
• p53, cellular proliferation, and apoptosis-related factors in thymic neuroendocrine tumors.